A multianalyte algorithmic assay (MAAA) identifies circulating neuroendocrine tumor (NET) transcripts (nZ51) with a sensitivity
Introduction
Biomarker assessment of gastroenteropancreatic neuroendocrine tumor (GEP-NET) disease has been difficult since the default is provided by a monoanalyte measurement, chromogranin A, which has well-described limitations (Lawrence et al. 2011 , Marotta et al. 2012 . The current scientific paradigm for biomarker development has focused on the advancement of multianalyte technologies (Engels et al. 2013 , Grimm et al. 2013 .
Endocrine-Related Cancer
This strategy facilitates the coupling of integral aspects of disease represented by individual markers into a mathematical algorithm that provides multidimensional clinical and pathobiological information inaccessible in a monoanalyte approach (Modlin et al. 2014a,b) .
In seeking to advance beyond a monoanalyte strategy, we developed a genetic biomarker assay in blood for GEP-NETs based upon qRT-PCR measurement of 51 circulating NET marker genes. Normalized gene expression is classified using four different learning algorithms (support vector machine, linear discrimination analysis, K-Nearest Neighbor, and Naive Bayes (Bayes)) and a score is assigned based on a majority vote (Modlin et al. 2013a) . Output is expressed as a 0-8 score, where a score O2 is classified as a GEP-NET (Modlin et al. 2014a,b) . The PCR test (NET score) is standardized and reproducible (inter-and intra-assay coefficient of variation (CV) !2%), and not affected by age, gender, ethnicity, fasting, or PPI medication (Modlin et al. 2014c ). The score is robust (inter-and intra-assay CV !2%; Modlin et al. 2014c ) with a high level of sensitivity and specificity (98 and 97% respectively). This multianalyte algorithmic assay (MAAA) strategy is significantly more accurate as a circulating biomarker than other currently utilized monoanalytes (Z-statistic 4.85-5.9, P!0.0001 vs e.g. chromogranin A and pancreastatin) for NET detection (Modlin et al. 2013a (Modlin et al. , 2014a .
Our current goal was to advance from a linear interpretation of disease activity based upon quantification of gene expression (0-8 score) to an amplified algorithm that incorporated gene clusters (GC) representative of NET neoplasia. This cluster integrated algorithm (CIA) would thus comprise both the diagnostic blood transcripts and include the mathematical expression levels of specific GC that delineate a variety of neoplastic biological processes, elegiacally referred to as the 'hallmarks of cancer' (Hanahan & Weinberg 2000 .
The 51 marker gene score includes a series of genes that are associated with neoplastic behavior. Captured by gene co-expression networks from tissue and blood transcriptome databases (Modlin et al. 2013a , these include biologically relevant transcripts involved in NET proliferation, signaling and secretion (Wulbrand et al. 1998 , Kidd et al. 2006 , Karhoff et al. 2007 , Drozdov et al. 2009 , Cui et al. 2010 , Muscarella et al. 2011 as well as genes reported to have a defined association with tumor initiation and metastasis (Hogarty et al. 2008 , Kim et al. 2008 , Miretti et al. 2008 , Naik et al. 2009 , Bralten et al. 2010 . As such, they overall provide 'omic' information.
The NET score provides a robust circulating 'fingerprint' for GEP-NET detection using a linear score (0-8).
It has not, however, been defined whether measurements of circulating transcripts functions as a multianalyte biomarker that correlates with tumor tissue expression levels. We postulated that if this was demonstrable, then the blood derived NET score could be used to define the real-time biological and clinically relevant state of a tumor. Thus, repetitive 'liquid biopsies' (blood sampling) would provide direct information about the tumor, its pathophysiology and its response to intervention. Therefore, a specific aim of the investigation was to define whether blood transcript levels directly correlated with tumor tissue levels collected at the same time point (i.e. at surgery). Hanahan & Weinberg (2000 have elegantly derived a synopsis of the complexity of cancer pathobiology by delineating a sequence of 'hallmarks' pathognomonic of neoplasia. These descriptors have been confirmed using systems biology approaches and 'cancer hallmark networks' can be quantified and computationally modeled to predict cancer evolutionary paths as well as clinical phenotypes. We utilized our pipeline to develop a systems biology approach to identify candidate NET biomarker genes. We hypothesized such genes would be 'neoplasia-relevant' and could be categorized using a 'hallmark' approach as a template. A mathematical algorithm (NETest) could then be derived that would capture the 'biology' of NET neoplasia. By inference, we would predict that the identification of such hallmarks would allow for extrapolation to provide clinically useful information. The corollary is that effective treatment protocols could be defined by their ability to modify transcript clusters or conversely ineffective agents would fail to perturb the cluster signatures. To this end, we examined whether the 51 marker gene panel could be mathematically reconfigured to include specific neoplastic defining 'hallmarks' or 'omes'. Our concept was to evaluate NET selectivity, determine whether tissue levels of these hallmarks were increased compared to non-neoplastic tissue and confirm that these GC could be not only measured in circulating blood samples but that they correlated with tissue expression levels. Finally, we sought to identify whether hallmark expression differed between two broad clinical groups currently characterized in clinical vernacular as stable disease (SD) or progressive disease (PD). Identification of biologically relevant 'omes' enabled us to expand on the original algorithm to include biologicallyrelevant gene expression data.
included sample set 1 which comprised nine NET transcriptomes (obtained from the small intestine) and normal small intestinal mucosa (Affymetrix U133A chips, nZ9 tumors and nZ3 normal mucosa, ArrayExpress: E-GEOD-6272) (Kidd et al. 2006 ) and sample set 2 which comprised six NET transcriptomes (Affymetrix U133 Plus2 chips, nZ3 primary midgut NETs and nZ6 normal mucosa, ArrayExpress: E-TABM-389) (Leja et al. 2009 ).
Other samples (groups 2 and 3) were collected and analyzed according to a standard IRB protocol (Yale University, 6/17/2013) in accordance with the World Medical Association Declaration of Helsinki (Modlin et al. 2013a) . Group 2 included 22 pathologically verified samples that were provided by Yale University (Surgical Pathology Tissue Databank per standard IRB protocol: Yale University, 6/17/2014) as well as normal mucosa (nZ8). The grade stage as well as previous treatment are included in Table 1 .
Matched blood samples were also available in nine. Group 3 included blood samples included in a training set (nZ130 (previously described); Modlin et al. 2013a) as well as samples from an independent set (nZ159: clinically stable disease (SD) nZ111; PD nZ48). The demographics of the 63 NETs in the training set were mean age 56 years (range: 18-80) and gender distribution (M:F) of 33:30. The 159 NETs in the independent set were mean age 57.1 years (range: 27-83), gender distribution (M:F) of 86:73. Tumor site, grade, stage, and treatment are included in Table 2 . The sets were well-matched, except the independent set had more pancreatic NETs (c 2 Z30, P!0.00001). Each group included both 'SD' and 'PD'. SD was assessed as per standard clinical criteria and RECIST criteria. The PD group (disease progression) was based on review of changes in radiological and nuclear medicine images at tumor board using the same criteria. PD was (Rindi et al. 2006 (Rindi et al. , 2007 . b Staged per ENETs criteria (Rindi et al. 2006 (Rindi et al. , 2007 . c Treatment included somatostatin analogs (SSA), interferon (IFN), or chemotherapy (chemo). d Microscopically and macroscopically normal mucosa. Samples were collected at surgery for the indicated diseases. All tissue was pathologically verified as 'normal'. e Included matched blood samples.
defined as any increase in tumor burden (any individual lesion), while SD was defined as no increase in tumor burden. The grade and stage distribution was not significantly different. All individuals who provided blood were (6/2009-3/2014) from the Yale School of Medicine, Smilow Cancer Center outpatient clinics and provided informed consent. Blood samples (5 ml) were collected in 9 mg K 2 EDTA tubes (BD Vacutainer Venous Blood Collection Tubes, BD Diagnostics, Franklin, NJ, USA). Aliquots of whole blood were stored at K80 8C within 2 h of collection (samples immediately stored on ice/4 8C after sampling) per standard molecular diagnostics protocols for PCR-based studies (Raza et al. 2012) .
Group 1: transcriptome assessment
Gene expression (fold change) of each of the target genes was examined in two publically available datasets, sample set 1 (Kidd et al. 2006 ) and sample set 2 (Leja et al. 2009 ). Individual analyses were performed using the web-based GeneProfiler tool (GeneProfiler, Bering Limited, http:// beringresearch.com/geneprofiler). Primary tumors were compared with non-matched normal mucosal samples. Sample set 1 consisted of 22 283 probes and 12 arrays, while sample set 2 consisted of 54 675 probes and 12 arrays. Probe sets that were unlikely to be reliable were eliminated using detection of present/absent calls. Probes present in O50% of samples were retained (McClintick & Edenberg 2006) . Raw probe intensities were normalized using the Robust Microarray Average approach (Irizarry et al. 2003) . Array outlier detection was performed in the array Quality Metrics package (Kauffmann et al. 2009 ) using the Kolmogorov-Smirnov statistic between each array's distribution and the distribution of the pooled data. To enhance microarray annotation, probe identifiers (IDs) were mapped to Entrez Gene IDs (accessed 7th April 2013; Maglott et al. 2011) . In cases where multiple probes mapped to the same Entrez ID, the average probe intensity was calculated. Probes without an Entrez record were removed from analysis. Genes that were consistently identified as differentially expressed using multiple ranking algorithms (Boulesteix & Slawski 2009 ; fold change ranking, ordinary t-statistic, shrinkage t-statistic, limma, significance analysis of microarrays) were called significant and retained for further analysis. This approach ensured that differential expression analysis was i) unbiased and ii) consistent across different array platforms.
Tissue RNA isolation and real-time PCR RNA was extracted (TRIzol, Invitrogen; Kidd et al. 2005 Kidd et al. , 2014 and real time RT-PCR analysis was performed using Assayson-Demand products and the ABI 7900 Sequence Detection System according to the manufacturer's suggestions (Kidd et al. 2005 . Cycling was performed under standard conditions (TaqMan Universal PCR Master Mix Protocol) and data normalized (using ALG9 and the DDC T method (Microsoft Excel)) using small bowel mucosa as a control. Samples were evaluated and scored using the MATLABderived protocol for blood (Modlin et al. 2013a (Modlin et al. ,b, 2014c . As a comparison normal tissue samples (nZ8) were included.
Blood-based MAAA PCR test
We used a two-step manual technique protocol (RNA isolation with cDNA production and qPCR). Transcripts 
CUP, carcinoid of unknown primary; ND, no data available; SI, small intestine. The grade and stage distribution was not significantly different between the stable and progressive disease groups. The majority O95% of patients were Caucasian. a Comparison of the two sets with the spectrum of disease included in the Surveillance Epidemiology and End Results (SEER) database (GEP-NETs) identified no significant differences indicating that the patient characteristics provided a reasonable reflection of the clinical spectrum of NET disease. b This included stable disease (nZ35) and progressive disease (nZ27). c This included stable disease (nZ111) and progressive disease (nZ48). d Primary location distribution was significantly different in the two sets (c 2 Z30.02, P!0.0001). Both the grade and stage were similar (c 2 Z1.3-2.9, PZ0.4-0.7). e GEP-NETs grade based on Ki67 or mitotic index (ENETs guidelines (Rindi et al. 2006 (Rindi et al. , 2007 ). BP grade based on WHO guidelines (Travis et al. 2004 ). f Stage based on ENETs guidelines (Rindi et al. 2006 (Rindi et al. , 2007 . Tumor disease was identified in lymph nodes, mesentery, liver, lung, bone, and ovary (or any combination thereof). Methodologies including octreoscan, computed tomography (CT), magnetic resonance imaging (MRI), identification at surgery, and identification at pathology, e.g. positive lymph nodes.
(mRNA) were isolated from 1 ml EDTA-collected blood samples using the mini blood kit (Qiagen). The RNA quantity was 50 ml, the quality was O1.8 (A 260:280 ratio); analysis of the RNA pattern on electrophoresis (Agilent Technologies, Santa Clara, CA, USA) RNA integrity number (RIN) O5.0 (Fleige et al. 2006) . The standard Qiagen isolation protocol (heme/gDNA contamination not detected) with no modifications was used. cDNA was produced from 50 ml RNA using a High Capacity Reverse Transcriptase Kit (Life Technologies: cDNA production 2000-2500 ng/ml) and stored at K80 8C. QPCR was performed (384-well plate, HT-7900) with the cDNA (200 ng/ml) and 16 ml of reagents/ well (Universal Master Mix II with UNG, Life Technologies, triplicate wells) (50 8C 2 min, 95 8C 10 min, then 95 8C 15 s, 60 8C, 60 s for 40 cycles) as described (Modlin et al. 2013a (Modlin et al. , 2014c . A NET score (0-8) was derived from the PCR data using MATLAB (R2011a, Mathworks, Natick, MA, USA; Modlin et al. 2013b); a value R2 is a positive tumor score (Modlin et al. 2013a (Modlin et al. ,b, 2014c . Quantification of gene expression in the clusters ('omes') was undertaken by summation of individual gene expression. For example, the 'SSTRome' comprises the summated gene expression of SSTR1, SSTR3, and SSTR5. Individual 'omes' that were significantly different (P%0.002) between SD and PD and were elevated in GEP-NET blood compared to control blood were included in an activity algorithm. Six 'omes' (SSTRome, proliferome, metabolome, secretome (II), epigenome, and plurome) met this criterion and were summated. Nonsignificant and therefore excluded 'omes' included secretome (I), signalome, and apoptome. A cut-off of 80 (summated normalized gene expression of six 'omes') based on receiver operating characteristic (ROC) analyses was used to differentiate disease phenotypes (SD vs PD). The original 0-8 score derived from the blood-based gene test that was used for the diagnosis of NETs was then reconfigured using the activity algorithm to generate a CIA. The latter was utilized to generate a disease activity range expressed as logarithmic basis of activity ranging from 0 to 100%. This was generated by weighting the original score by whether it was 'stable' or 'progressive'. Scores of 0-8 with 'stable' phenotype were converted to 0-44% (low activity); those with 'progressive' phenotype ranged from 44 to 100% (high activity).
Statistical analysis
Sensitivity comparisons using c 2 , non-parametric measurements and ROC analysis were made between the standard MAAA-PCR and NETest. Both Prism 6.0 for Windows (GraphPad Software, La Jolla, CA, USA, 
Results

Assessment of circulating NETest genes expression in NET tumor tissue
To confirm the 51 marker gene blood panel captured NET genes, we examined gene expression in two publically available datasets (Kidd et al. 2007 , Leja et al. 2009 ). All 51 genes were identified. Forty-five (92%) were elevated in NETs compared to normal mucosa at a transcriptome level ( Fig. 1A) . A second group of pathologically verified GEP-NET samples (nZ22) examined by qRT-PCR identified 50 of 51 genes (98%) to be elevated in NETs compared to normal mucosa (Fig. 1B) . Examination of normal tissue (nZ8) demonstrated all to score between 0 and 2, thus none were classified as NETs (Modlin et al. 2013a (Modlin et al. , 2014a ; Table 3 ). Twenty-two (100%) of the pathologically verified tumor samples exhibited scores O2 and were classified as NETs per protocol (Modlin et al. 2013a (Modlin et al. , 2014a ; Table 3 ). A subanalysis of different organ sites identified that the NET score accurately (100%) classified samples from the stomach (1/1: activity: 80%), pancreas (4/4: 55G3%), small intestine (10/10: 52G6%), appendix (1/1: 47%), and rectum (6/6: 58G3%).
Correlation between circulating and tissue NETest genes
Pre-surgical blood samples were available for nine of the 22 pathologically verified tumor tissue samples (staging included: I (nZ1), II (nZ3), and IV (nZ5). Seven control blood (non-NET) and matched normal mucosa were also available. Comparison analysis identified that the blood NET scores closely correlated (two-tailed non-parametric correlation analysis Spearman), rZ0.804, PZ0.0004 with tumor tissue samples. In addition, the accuracy, i.e. the ability of the scores to classify a sample as either 'normal' or 'tumor' for matched tissue and blood samples, was 100% ( Fig. 2A ). An assessment of each of the 51 marker genes individually identified significant expression correlation in tumor tissue and blood respectively. Representative samples from stomach, pancreas, small intestine and rectum are included (linear regression analysis (Pearson), goodness of fit R 2 Z0.09-0.26, PZ0.002-0.04; Fig. 2B ).
Derivation and tissue expression of the NET 'hallmarks'
Thirty of the 51 genes (58%) could be classified into nine 'hallmarks' or GC (Table 4 ). Clusters were based on a combination of classical descriptors (Hanahan & Weinberg 2000 as well as the protein: protein interactome network (Franceschini et al. 2013 . A heat map analysis of each of the clusters or 'omes' identified expression was higher in NETs than in normal mucosa (Fig. 3A) . Expression in 22 NETs when compared to normal mucosa (nZ8) identified that seven of the clusters were specific to NETs (Fig. 3B , *P!0.01, **P!0.05 Mann-Whitney U test, two tailed). Fold change analysis (Mann-Whitney U test, two tailed) identified significant increases in seven clusters. One cluster, the 'plurome', was significantly reduced in tumor tissue compared to normal mucosa, while the proliferome was similar between NETs and normal tissue (Fig. 3C ).
Correlation of NET 'Hallmarks' between tumor tissue and blood
We next examined 'omes' in the nine matched tumor and blood samples to examine correlation. No significant differences were noted between clusters in tissue and blood (PZ0.11, Wilcoxon matched-pairs signed rank test, r s (Spearman effectiveness of pairing): 0.41, PZ0.0026 (one-tailed)). Individual 'omes' were higher in blood than tissue except for the secretome (Fig. 4A ). No significant differences were noted between each of the individual 'omes' in blood and tissue (PZ0.1-0.9; Wilcoxon matchedpairs signed rank test).
Clinical utility of clustered gene expression
Thereafter, we assessed the expression of each of the 'omes' in peripheral blood samples to examine whether expression levels were related to clinically defined SD or PD as determined by best clinical judgment and/or imaging data.
In the test set (initially used to develop the NET score (Modlin et al. 2013a ; nZ130: controls: nZ67, NETs: nZ63 (SD: nZ35 and PD: nZ28)), significant differences were noted in 'omes'. Non-parametric testing (Kruskal-Wallis) identified that eight of the 'omes' differed (PZ0.01-P!0.0001, Kruskal-Wallis statistic: 9.1-51.7 (Table 5 ). The metabolome was not identified to be different in this analysis (PZ0.43). Multiple testing with adjustments (Dunn's multiple testing comparison) identified where SD or PD were significantly different and when they differed to controls. Data are included in Fig. 4B . These data demonstrate that GC not only differentiate SD and PD from controls but segregate the two clinical groups of SD and PD. We next examined cluster gene results in the independent set (nZ159: including SD: nZ111 and PD: nZ48), evaluating each of the clusters in SD vs PD. In this set, the SSTRome, proliferome, secretome (II), plurome, and epigenome were significantly increased (P!0.05, Mann-Whitney U test) in PD compared to SD (Fig. 4C ). Receiver operator curve analysis of the combined dataset (test and independent sets) identified that the AUC for differentiating SD (nZ146) from PD (nZ75) was significant for seven of the omes (AUC: 0.65-0.72, P!0.0002, Table 5 ). This was not significant for the growth factor signalome or the general secretome. These data confirm that GC expression can be used to differentiate between SD and PD.
Cluster analysis integration into the blood multianalyte algorithm
We examined the NET scores (0-8) of the complete patient group (test setCindependent set: nZ222; excluding controls) in SD vs PD. In the SD group (nZ146), the highest frequency score was 4 (30%, Fig. 5A ), while 46% of PD group (nZ75) had a score of 8 ( Fig. 5A) . A risk probability assessment identified that NET scores ranging from 0 to 5 were associated with SD with a R90% certainty (Fig. 5B) . A score of 8 was considered as PD (O90%). However, scores of 6 and 7 could not accurately differentiate SD vs PD. We next examined whether individual 'omes' could differentiate between SD and PD. ROC analyses identified that the AUC's ranged from 0.514 (secretome I) to 0.72 (plurome) ( Table 4 and Fig. 5C ).
The omes (nZ6) that were significantly increased (P%0.002) in PD compared to SD were then included in an activity algorithm (omes were summated into a single score). The 'apoptome' was excluded since it was decreased compared to control blood (Fig. 4B ). The resultant activity algorithm was tested in the combined set and noted to have an AUC of 0.81G0.03 (95% CI: 0.753-0.861), P!0.0001 (Fig. 5D ) for differentiating between PD and SD.
The clinical utility of this algorithmic reconfiguration was then assessed by re-evaluating the original MAAA derived 0-8 score. We weighted the 0 to 8 score by whether the sample was called SD or PD by the algorithm. 
Blood (2) Blood (3) Blood ( This allowed the development of a 0-100% activity score that incorporated both the machine-learning derived 0-8 score with the additional information regarding disease activity (as captured in the 'ome' algorithm; Fig. 6A ). The distribution of activity scores is included in Fig. 6B . PD samples had significantly higher activity scores than SD samples (83.7G24.4% vs 34.1G27%, P!0.0001). The upper 95% CI for SD was 45% indicating this could be used as a cut-off to differentiate PD from SD. Using this value (45%), the accuracy was 87.4% for predicting disease status as stable or progressive. The metrics for this, undertaken in the same set (nZ222), were sensitivity: 91.1%, specificity: 85.3%, positive predictive value: 77.4%, and negative predictive value: 94.6% (Fig. 6C ). ROC analysis demonstrated an AUC of 0.92G0.02 (95%CI: 0.88-0.96), P!0.0001. A comparison between the CIA NETest (0-100%) and the NET score (0-8) demonstrated the former to be significantly more informative, i.e. the T1   T2   T3   T4   T5   T6   T7   T8   T9   T10   T11   T12   T13   T14   T15   T16   T17   T18   T19   T20 difference between AUC: 0.04G0.013, Z-statisticZ3.139, PZ0.00017 ( Fig. 6D ). Of particular note was that the higher NET scores (6-7), which previously could not accurately differentiate SD vs PD could now be accurately differentiated (93%) by the activity-based index.
Discussion
It is clear that monoanalyte biomarkers such as chromogranin A have significant limitations in the diagnosis and management of NETs (Marotta et al. 2012) . Having developed an effective multianalyte strategy for NET disease diagnosis, we sought to amplify the utility of this diagnostic by incorporating tumor-derived biological and gene network information. Our current investigations assess whether measurements of circulating transcripts directly correlated with tumor tissue expression levels and whether this 'liquid' biopsy could yield further information about the biological map ('hallmarks') of the tumor. Ultimately, we sought to demonstrate that a CIA blood measurement would be able to identify and differentiate clinically SD from PD. Our results demonstrated that circulating transcripts detectable in blood were expressed in and significantly correlated with tumor tissue irrespective of the origin. While the number of tumor samples from individual sites was limited, the distribution is broadly representative of the populations typically seen in clinical practice. Biologically relevant hallmarks (GC/omes) were also identified and shown to have concordance between blood and tumor tissue. The integration of this information with the original MAAA (NET score 0-8) enabled the development of a more sophisticated tool, a disease activity scale (0-100%) called the NETest. This numeric exhibits a high sensitivity and specificity (91 and 85% respectively) for delineating GEP-NET disease activity. The demonstration that this signature is also applicable to bronchopulmonary NETs, suggests its likely utility in the evaluation of these tumors but this requires further evaluation. The use of PCR to determine transcript alterations, e.g. gene fusions in acute myeloid leukemia 1 (AML1)/ETO or BCR-ABL in peripheral blood, is now a standard approach in hematological cancers (Oehler & Radich 2006 , Zhang et al. 2014 . Similar methodologies are evolving for solid tumors, e.g. MACC1 in gastric cancers (Burock et al. 2015) or a panel of prostate cancer-associated genes in prostate cancer (Danila et al. 2014) . Hematological cancer measurements clearly reflect a pathobiological process as expression of fusion transcript levels correlate well (R 2 Zw0.5) between bone marrow and blood (Ostergaard et al. 2004 ). However, it is unclear whether measurements of solid tumor-associated transcripts reflect actual carcinoma tissue expression or capture other aspects of tumor biology, e.g. gene expression from non-tumor cells in the tumor microenvironment. We specifically assessed the 51 marker gene expression in NET tumor tissue and identified that levels were elevated in 22 tumors from different GEP sites compared to macroscopically normal mucosa. Ninety-eight percent of transcripts exhibited elevated expression in the tumor samples identifying that transcripts were neuroendocrine-selective. Furthermore, expression of the 51 transcripts could be detected and measured in circulating blood and expression levels exhibited a significant correlation (RZw0.3, P!0.05) with tissue levels irrespective of the origin demonstrating this was a pan-NET signature. Importantly, the NET-derived score in blood was well-correlated (Spearman rO0.8, P!0.0005) with tissue. Furthermore, it was completely accurate (100% samples correctly called as either tumor or normal). These results confirm that circulating transcripts detectable in blood are also expressed in and correlate significantly with GEP-NET tissue expression levels.
We next focused on the 'hallmarks' of NETs. The complexity of cancer has been reduced to a defined number of underlying principles (Hanahan & Weinberg 2000) which have been recently updated (Hanahan & Weinberg 2011) . This approach has been transposed to NET disease (Walenkamp et al. 2014) . Using networking analysis, cancer hallmarks can be signified by molecular networks which have the advantage of allowing quantification and computational modeling . These networks interact with each other during cancer cell evolution and may thus be considered to define or regulate the evolution of a tumor. Interrogation of such interactions can be quantified and then computationally modeled to predict cancer evolutionary paths and clinical phenotypes. Using this strategy, network operational signatures have been proposed to compute and model the measures of hallmark traits and this systems biology approach identified nine networks . We applied this stratagem to assess the 51 NET marker genes. Our literature-curated analysis and unbiased protein:protein interactome approach which includes information from all neoplasia identified that thirty of the 51 genes (58%) could be classified into nine hallmarks or GC network signatures (Table 3) . The remainder were not categorized as cancer-relevant hallmarks based on our current understanding of neoplasia. Some of these genes have been identified in NETs, e.g. Ki67 and nucleosome assembly protein-like 1 (NAP1L1) as markers of proliferation (Kidd et al. 2006 , Rindi & Wiedenmann 2011 and mechanistically linked to the epigenome (Schimmack et al. 2014) . Growth factor expression and signaling is a well-known regulator of NET proliferation (Kidd et al. 2005 ) and signaling pathways (e.g. the RAS/RAF/MAPK signaling pathway) is typically activated (Perren et al. 2004 , Tannapfel et al. 2005 while expression of the BRAF activator Rap1 as well as B-Raf itself can be detected by immunohistochemistry (75%) (Karhoff et al. 2007) . Other examples include secretion, e.g. PNMA2 as well as somatostatin receptor expression, both of which have been described in NETs (Reubi et al. 2001 , Cui et al. 2010 .
Initially, we assessed whether the hallmarks or 'omes' exhibited an elevated expression in NET tissue and identified that seven were elevated compared to normal mucosa, with one significantly reduced in tumor tissue compared to normal mucosa (the 'plurome'). We interpreted this observation as evidence that the cancer network-based signatures were selective for NETs compared to normal mucosa, which has been defined as a dynamic, well-regulated tissue with active regulated turnover (Gracz & Magness 2014) . Of clinical relevance, however, was the observation that no significant differences were noted between cluster analysis in matched tissue and blood (PZ0.11) although individual 'omes' were generally higher in blood than tissue except for genes involved in secretion (secretome). Differences in transcript expression between tissue and blood are not unusual and have previously been noted in bone marrow diseases where expression levels of certain fusion genes can be three to five times higher in the circulation than in marrow while others may be one to two times lower (Ostergaard et al. 2004) . While the mechanism behind these differences is unknown, the higher levels we noted in the circulation were not significantly different to that measured in tumor tissue.
Having determined that the genes could be classified into a cancer network and using the premise that disease activity is linked to cluster expression, we next sought to identify whether GC expression/omes could define clinical disease. We therefore examined the question of whether disease categorized as clinically stable could be differentiated from active, PD by GC/ome expression. The NET specificity of the 'omic' expression was indicated by the elevated expression of the majority, e.g. proliferome, signaling and SSTRome in NETs compared to control blood in the test set. Furthermore, in an independent set (nZ159), the SSTRome, proliferome, secretome, plurome, and epigenome were all significantly increased (P!0.05) in the PD (Fig. 4C) . These observations were consistent with our hypothesis that a circulating gene signature captures biologically relevant data that would correlate with clinical and imaging-based assessment of NETs. Measurements of individual 'omes' were individually informative with AUC's ranging from 0.514 (secretome I) to 0.72 (plurome). However, when mathematically combined as a group (into an activity algorithm), the information was highly informative with an AUC of 0.81 for differentiating between PD and clinically SD.
In previous reports, we have detailed the development of a highly accurate diagnostic test for NETs (sensitivity and specificity: 98 and 97% respectively; Modlin et al. 2013a Modlin et al. , 2014a based on a 0-8 score derived from four different prediction algorithms. This investigation sought to evaluate whether the inclusion of the informative clusters (biological data) would amplify the diagnostic potential and provide a predictive component to the assessment of disease activity. To accomplish this, we adopted a weighted approach, similar to that successfully used for measuring/predicting prognosis in non-small cell lung cancer (a five gene and protein signature; Kadara et al. 2011) . In our approach, we weighted the 0-8 score by whether the GC activity algorithm identified the sample as 'active' and therefore 'progressive' or exhibited a low activity gain and was clinically stable. We expressed this coefficient of activity as a 0-100 score for which the discriminant index was significantly more effective at segregating the two clinical phenotypes. Adoption of this mathematical strategy provided an AUC of 0.92, with CIA NETest metrics of sensitivity: 91.1%, specificity: 85.3%, positive predictive value: 77.4%, and negative predictive value: 94.6%. This was significantly more accurate than use of the 0-8 score alone (Z value: 3.1, P!0.002) and efficiently differentiated individuals with indeterminate scores of 6 and 7 into high probability (93%) SD or PD.
We developed an accurate blood-based multianalyte transcript diagnostic tool for NETs and now report further refinement by inclusion of 'omic' expression cluster analysis from NET-derived cancer networks. Integration of cluster analysis provides a significantly more effective methodology to facilitate a real-time predictive assessment of NET disease status. In most patients, grading and classification of tumor type is based upon one-time assessment of the primary lesion. This also provides a resource to determine the genetic basis of the disease which may impact treatment as well as behavior. Somatic mutations in genes including MEN1, ATRX, DAXX as well as in mTOR signaling (Leotlela et al. 2003) and in the zinc finger YY1 (Cao et al. 2013) have been identified in pancreatic NETs while inactivation of CDKN1B (P27 KIP1 ) has been noted in small intestinal NETs (Francis et al. 2013) . ATRX and DAXX are associated with a reduced time of relapse-free survival and a decrease in survival (Marinoni et al. 2014) while mutations in YY1 are associated with a later onset of tumors (Cao et al. 2013) . CDKN1B loss is associated with a decreased survival and reported as an independent factor in poor overall survival (Kim et al. 2014) . Protein:protein interactome analyses demonstrate that mutations in these genes that characterize the genetic basis of NET disease can be captured by the circulating signature. The pancreas-restricted mutations are all linked to chromatin remodeling ('epigenome') while MEN1 and CDKN1B are involved in growth factor signaling and proliferation ('signalome' and 'proliferome'). The somatic SNVs identified in small intestinal NETs also include genes that impact the different NET 'omes' including FGFR2 ('signalome'), EZH2 ('signalome' and 'proliferome') or actually comprise directly the signature itself, e.g. BRAF. Therefore, the circulating NET signature has the capacity to both identify NET-specific genetic alterations as well as provide information relevant to targetable signaling pathways, e.g. mTOR ('signalome'). This bloodbased multianalyte strategy directly reflects tumor tissue biological activity and provides accurate time-specific information that reflects the status of evolving disease (residual or metastases). It is likely that such information will also reflect the efficacy of any therapeutic intervention and thereby provide valuable clinical information to facilitate management. The early identification of active, progressing disease has obvious clinical implications. In those with residual disease, the identification of increased disease activity or diminished treatment efficacy is clinically of considerable relevance to management. Similarly, clinicians utilizing targeted therapies would benefit from quantification of biologically relevant 'omes', e.g. RAF/RAS signaling or somatostatin receptor expression that provide assurance of the presence of a relevant therapeutic target and demonstration of efficacy. For example, PCR-based molecular monitoring of AML has identified that a lack of decline of transcript levels by less than two logs after chemotherapy is a poor prognostic sign (Jaeger & Kainz 2003) . In chronic myeloid leukemia, PCR-based tests that detect the BCR-ABL chimeric transcript predict relapse in the transplant setting are a strong measure in predicting progression-free survival in imantinib-treated patients (Oehler & Radich 2006) . Trials using the quantitative assessment of BCR-ABL as a surrogate outcome marker will examine if such strategies can reduce both the time and cost of clinical trials (Oehler & Radich 2006) .
We have demonstrated that gene expression, measured in blood, reflected tissue expression, that expression of genes in the NETest captured the biology of NET neoplasia, and that integrating these measurements of circulating gene expression could accurately define clinical status. Based on these data, which indicate that measurement of circulating gene expression is clinically informative, we have built an algorithm -the NETEst -that not only accurately diagnoses GEP-NETs but also provides a measure of their biological activity.
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